Christopher B. Ehrlich, Director at eFFECTOR Therapeutics, Inc. (EFTR), bought 18,867 shares at $0.55 ($10K) on 2022-09-26, disclosed to the SEC on 2022-09-27.
Open-market purchase of $10k EFTR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Clearly above the average filing.
| Filing → |
| EFTR | BUY | 2022-02-10 | $10K | — | Filing → |
| EFTR | BUY | 2022-02-07 | $31K | — | Filing → |
| EFTR | BUY | 2022-01-31 | $27K | — | Filing → |